Business Context and Reporting Period
This Form 8-K is a current report filed by OvaScience, Inc. (noted as Tempest Therapeutics in metadata) on December 7, 2015, covering events occurring between December 2 and December 7, 2015. The company is a Delaware corporation headquartered in Waltham, MA, focused on fertility treatments including OvaPrime and OvaTure.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses on executive compensation adjustments and operational milestones rather than financial statement data.
Material Changes
- Executive Compensation: Jeffrey Young's annual base salary was increased from $315,000 to $380,000. His target annual cash bonus was raised from 35% to 50% of his annual salary.
- Equity Grant: On December 3, 2015, Mr. Young was granted 50,000 restricted stock units (RSUs) vesting over four years (25% on December 3, 2016, and 6.25% quarterly thereafter).
- Operational Milestone: The company announced it achieved its 2015 goals for its OvaPrime and OvaTure fertility treatments.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) confirming the achievement of 2015 goals for key products. No specific forward-looking financial guidance, risk factors, or contingencies are detailed within the text of this 8-K.
Investor Verification Checklist
- Verify the full text of the December 7, 2015 press release (Exhibit 99.1) for details on the specific 2015 goals achieved.
- Review the company's most recent 10-K or 10-Q for comprehensive financial data, as this 8-K contains no financial statements.
- Confirm the vesting schedule and valuation of the 50,000 RSUs granted to the CFO.